Abivax S.A. — Investor Relations & Filings
Abivax S.A. is a clinical-stage biotechnology company focused on developing therapeutics for chronic inflammatory diseases by harnessing the body's natural regulatory mechanisms. The company's core strategy revolves around modulating the immune response through microRNA (miRNA). Its lead drug candidate, obefazimod, is an investigational, orally administered small molecule with a novel mechanism of action. Obefazimod is designed to enhance the expression of miR-124, a key microRNA that regulates the inflammatory response. The primary development goal is the commercialization of obefazimod for the treatment of ulcerative colitis, with clinical programs also underway for Crohn's disease. The company is exploring obefazimod for other inflammatory indications and is investigating follow-on compounds from its proprietary chemical library.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 6-K | 2026-05-22 | English | |
| 6-K | 2026-05-20 | English | |
| 6-K - Abivax S.A. (0001956827) (Filer) | 2026-05-07 | English | |
| 424B7 - Abivax S.A. (0001956827) (Filer) | 2026-05-07 | English | |
| S-8 - Abivax S.A. (0001956827) (Filer) | 2026-03-23 | English | |
| 20-F - Abivax S.A. (0001956827) (Filer) | 2026-03-23 | English |
Browse filings by year
5 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
10 filings
| |||||
| 46859106 | 6-K | 2026-05-22 | English | ||
| 46692793 | 6-K | 2026-05-20 | English | ||
| 43481539 | 6-K - Abivax S.A. (0001956827) (Filer) | 2026-05-07 | English | ||
| 43132807 | 424B7 - Abivax S.A. (0001956827) (Filer) | 2026-05-07 | English | ||
| 33016665 | S-8 - Abivax S.A. (0001956827) (Filer) | 2026-03-23 | English | ||
| 33016505 | 20-F - Abivax S.A. (0001956827) (Filer) | 2026-03-23 | English | ||
| 33016424 | 6-K - Abivax S.A. (0001956827) (Filer) | 2026-03-23 | English | ||
| 32249312 | SCHEDULE 13G/A Filing | 2026-02-13 | English | ||
| 13630008 | Major Shareholding Notification 2026 | 2026-01-14 | English | ||
| 13630005 | Regulatory Filings 2026 | 2026-01-08 | English | ||
|
2025
5 filings
| |||||
| 13630007 | 6-K | 2025-12-15 | English | ||
| 13630010 | Major Shareholding Notification 2025 | 2025-11-14 | English | ||
| 13630009 | Major Shareholding Notification 2025 | 2025-11-14 | English | ||
| 13630012 | Major Shareholding Notification 2025 | 2025-10-30 | English | ||
| 13630011 | Regulatory Filings 2025 | 2025-10-28 | English | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
BIOCRYST PHARMACEUTICALS INC
Develops novel medicines for patients with rare and serious…
|
BCRX | US | Manufacturing |
|
Biocure Technology Inc.
Develops and commercializes advanced biological medicines, …
|
CURE.X | CA | Manufacturing |
|
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Develops novel antibody-based drugs and provides integrated…
|
2315 | HK | Manufacturing |
|
Biodexa Pharmaceuticals Plc
Clinical-stage biopharma developing treatments for rare dis…
|
BDRX | GB | Manufacturing |
|
BioDlink International Company Limited
Integrated biopharmaceutical CDMO specializing in ADC platf…
|
1875 | HK | Manufacturing |
|
BioEnvelop Technologies Corporation
Developed rapidly dissolving edible film strips for nutrace…
|
BIE | CA | Manufacturing |
|
Biofarm S.A.
A pharmaceutical company that manufactures and markets medi…
|
BIO | RO | Manufacturing |
|
BIO-FD&C CO.,LTD.
Develops active ingredients for cosmetics and pharma using …
|
251120 | KR | Manufacturing |
|
Biofil Chemicals & Pharmaceuticals
Produces pharmaceutical formulations, bulk drugs, and plast…
|
BIOFILCHEM | IN | Manufacturing |
|
Biofrontera AG
Biopharmaceutical firm specializing in photodynamic therapy…
|
B8F | DE | Manufacturing |
Abivax S.A. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/30868/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=30868 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=30868 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=30868 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 30868}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Abivax S.A. (id: 30868)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.